author-photo

Andrea Pirzkall

Genentech

36

Papers

1268

Citations

Citation Trend

Filter By

Papers (25) Sort By

Journal Conference Others

Investigation of the Absolute Bioavailability and Human Mass Balance of Navoximod, a Novel IDO1 Inhibitor

2019 British Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (3)
Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis

2019 JAMA Ophthalmology
Show All
- Source
- Cite
- Save
Citations (9)
A phase 3, open-label, multicenter, randomized study to investigate the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus docetaxel in patients with non-small cell lung cancer who have progressed on a prior platinum-containing regimen.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (22)
Identification of head and neck cancers (SCCHN) that may respond to dual inhibition of EGFR and HER3 signaling.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
A phase ib dose-escalation study of the safety, tolerability, and pharmacokinetics of cobimetinib and duligotuzumab in patients with previously treated locally advanced ormetastatic cancers with mutant KRAS

2017 Oncologist
Show All
- Source
- Cite
- Save
Citations (13)
Human pharmacokinetic (PK) characterization of the novel dual-action anti-HER3/EGFR antibody MEHD7945A (MEHD) in patients with refractory/recurrent epithelial tumors.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 5155: Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck

2016 Cancer
Show All
- Source
- Cite
- Save
Citations (23)
Randomized phase II study of duligotuzumab plus FOLFIRI versus cetuximab plus FOLFIRI in 2nd-line patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)

2015
Show All
- Source
- Cite
- Save
Citations (4)